

Michelle Ann Lally

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7523768/publications.pdf>

Version: 2024-02-01

58
papers

2,621
citations

236925

25
h-index

189892

50
g-index

59
all docs

59
docs citations

59
times ranked

3871
citing authors

#	ARTICLE	IF	CITATIONS
1	Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2022, 249, 12-22.	2.7	1
2	Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 193-198.	2.5	54
3	Age at Diagnosis of Heart Failure in United States Veterans With and Without HIV Infection. <i>Journal of the American Heart Association</i> , 2021, 10, e018983.	3.7	4
4	Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection. <i>JACC: Heart Failure</i> , 2020, 8, 501-511.	4.1	9
5	Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	8
6	Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. <i>AIDS and Behavior</i> , 2018, 22, 1174-1183.	2.7	36
7	A Mobile Gaming Intervention to Increase Adherence to Antiretroviral Treatment for Youth Living With HIV: Development Guided by the Information, Motivation, and Behavioral Skills Model. <i>JMIR MHealth and UHealth</i> , 2018, 6, e96.	3.7	47
8	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	6.2	178
9	HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. <i>AIDS Patient Care and STDs</i> , 2017, 31, 504-516.	2.5	52
10	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	2.1	235
11	State-civil society partnerships for HIV/AIDS treatment and prevention in Ghana: exploring factors associated with successes and challenges. <i>BMC Health Services Research</i> , 2016, 16, 332.	2.2	6
12	Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth. <i>AIDS Patient Care and STDs</i> , 2016, 30, 339-348.	2.5	41
13	Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. <i>Journal of Clinical Investigation</i> , 2016, 126, 3117-3129.	8.2	5
14	Avatar Web-Based Self-Report Survey System Technology for Public Health Research: Technical Outcome Results and Lessons Learned. <i>Online Journal of Public Health Informatics</i> , 2016, 8, e189.	0.7	0
15	HIV testing and linkage to services for youth. <i>Journal of the International AIDS Society</i> , 2015, 18, 19433.	3.0	83
16	Profiles of Medicinal Cannabis Patients Attending Compassion Centers in Rhode Island. <i>Journal of Psychoactive Drugs</i> , 2015, 47, 18-23.	1.7	32
17	Adolescent decision making about participation in a hypothetical HIV vaccine trial. <i>Vaccine</i> , 2015, 33, 1331-1337.	3.8	18
18	Clinician Attitudes Toward CDC Interim Pre-Exposure Prophylaxis (PrEP) Guidance and Operationalizing PrEP for Adolescents. <i>AIDS Patient Care and STDs</i> , 2015, 29, 193-203.	2.5	47

#	ARTICLE	IF	CITATIONS
19	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	7.1	376
20	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. Vaccine Journal, 2014, 21, 1589-1599.	3.1	10
21	Evaluation of an Intervention Among Adolescents to Reduce Preventive Misconception in HIV Vaccine Clinical Trials. Journal of Adolescent Health, 2014, 55, 254-259.	2.5	19
22	Bundling Human Papillomavirus Vaccination and Rapid Human Immunodeficiency Virus Testing for Young Gay and Bisexual Men. LGBT Health, 2014, 1, 233-237.	3.4	10
23	Web-based, mobile-device friendly, self-report survey system incorporating avatars and gaming console techniques. Online Journal of Public Health Informatics, 2014, 6, e191.	0.7	3
24	Integrating Behavioral HIV Interventions Into Biomedical Prevention Trials With Youth: Lessons From Chicago's Project PrEPare. Journal of HIV/AIDS and Social Services, 2013, 12, 333-348.	0.7	18
25	The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 447-456.	2.1	159
26	Preventive misconception and adolescents' knowledge about HIV vaccine trials. Journal of Medical Ethics, 2013, 39, 765-771.	1.8	24
27	Correlates of willingness to participate in microbicide research among African Americans. Journal of Health Psychology, 2013, 18, 65-74.	2.3	8
28	OPRM1 and Diagnosis-Related Posttraumatic Stress Disorder in Binge-Drinking Patients Living with HIV. AIDS and Behavior, 2012, 16, 2171-2180.	2.7	19
29	Quantitative proteomic analysis of exosomes from HIV-infected lymphocytic cells. Proteomics, 2012, 12, 2203-2211.	2.2	42
30	Keeping the Faith: African American Faith Leaders' Perspectives and Recommendations for Reducing Racial Disparities in HIV/AIDS Infection. PLoS ONE, 2012, 7, e36172.	2.5	63
31	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131
32	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases, 2011, 203, 1165-1173.	4.0	71
33	Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, S31-S42.	2.1	25
34	HPV Vaccination Practices Among Juvenile Justice Facilities in the United States. Journal of Adolescent Health, 2010, 46, 495-498.	2.5	17
35	Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B ₁ gag Vaccines in Healthy Adults. AIDS Research and Human Retroviruses, 2009, 25, 103-114.	1.1	63
36	Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV ₁ Clade B ₁ gag/pol/nef Vaccine in Healthy Adults. Clinical Infectious Diseases, 2008, 46, 1769-1781.	5.8	215

#	ARTICLE	IF	CITATIONS
37	HIV Seroconversion without Infection after Receipt of Adenovirus-Vectored HIV Type 1 Vaccine. <i>Clinical Infectious Diseases</i> , 2008, 47, 1593-1599.	5.8	21
38	A Qualitative Study Among Injection Drug Using Women in Rhode Island: Attitudes Toward Testing, Treatment, and Vaccination for Hepatitis and HIV. <i>AIDS Patient Care and STDs</i> , 2008, 22, 53-64.	2.5	42
39	Feasibility and Acceptability of Rapid HIV Testing in Jail. <i>AIDS Patient Care and STDs</i> , 2007, 21, 41-47.	2.5	55
40	Vaccination in Juvenile Correctional Facilities: State Practices, Hepatitis B, and the Impact on Anticipated Sexually Transmitted Infection Vaccines. <i>Public Health Reports</i> , 2007, 122, 44-48.	2.5	8
41	HPV Vaccination an Opportune Time for HIV Testing. <i>Journal of Adolescent Health</i> , 2007, 40, 384.	2.5	2
42	HIV vaccine update: recent developments and current trials. <i>Medicine and Health, Rhode Island</i> , 2007, 90, 318-20.	0.1	0
43	Where to begin human papillomavirus vaccination?. <i>Lancet Infectious Diseases, The</i> , 2006, 6, 389-390.	9.1	3
44	Willingness to receive an HIV vaccine among incarcerated persons. <i>Preventive Medicine</i> , 2006, 43, 402-405.	3.4	7
45	A Model to Provide Comprehensive Testing for HIV, Viral Hepatitis, and Sexually Transmitted Infections at a Short-Term Drug Treatment Center. <i>AIDS Patient Care and STDs</i> , 2005, 19, 298-305.	2.5	11
46	Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. <i>Methods</i> , 2004, 34, 476-487.	3.8	42
47	A review of the case for hepatitis B vaccination of high-risk adults. <i>American Journal of Medicine</i> , 2003, 114, 316-318.	1.5	53
48	Routine, Not Risk-Based, Human Immunodeficiency Virus Testing Is the Way to Go. <i>Journal of Infectious Diseases</i> , 2003, 187, 1024-1024.	4.0	3
49	Acceptability of Sexually Transmitted Infection Screening Among Women in Short-Term Substance Abuse Treatment. <i>Sexually Transmitted Diseases</i> , 2002, 29, 752-755.	1.7	19
50	HIV Risk Behaviors in Adolescent and Young Adult Substance Users Undergoing Treatment. <i>Journal of HIV/AIDS Prevention and Education for Adolescents and Children</i> , 2002, 4, 43-54.	0.1	1
51	Routine HIV Testing Among Inpatients. <i>Archives of Internal Medicine</i> , 2002, 162, 2252-2253.	3.8	10
52	HIV TESTING IN THE SETTING OF INPATIENT ACUTE SUBSTANCE ABUSE TREATMENT. <i>American Journal of Drug and Alcohol Abuse</i> , 2001, 27, 491-499.	2.1	11
53	HIV Testing Among Young Adults and Older Adolescents in the Setting of Acute Substance Abuse Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 135-142.	2.1	3
54	Risk Factors for Syphilis among Incarcerated Women in Rhode Island. <i>AIDS Patient Care and STDs</i> , 2001, 15, 581-585.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Comprehensive Medical Care among HIV-Positive Incarcerated Women: The Rhode Island Experience. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2000, 9, 51-56.	1.5	36
56	Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. <i>American Journal of Medicine</i> , 2000, 109, 568-576.	1.5	109
57	<i>Legionella bozemanii</i> Pneumonia in Three Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1998, 27, 97-99.	5.8	29
58	Hypercalcemia in an AIDS patient treated with growth hormone. <i>Aids</i> , 1997, 11, 1353-1356.	2.2	12